CLAIMS

1. A pharmaceutical composition comprising:

one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25°C and 70% relative humidity; and

oseltamivir phosphate,

wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.

2. The pharmaceutical composition according to claim 1, wherein the excipient is one sugar or sugar alcohol selected from erythritol, D-mannitol and sucrose or a mixture thereof.

3. The pharmaceutical composition according to claim 1 or 2, wherein the composition is used for prevention or treatment of influenza virus infection and conditions associated with the infection selected from bronchitis, pneumonia, generalized pain and fever.

4. The pharmaceutical composition according to any one of claims 1 to 3, further comprising one or more water-soluble polymers selected from povidone, methylcellulose, carmellose sodium and macrogol 6000.

5. The pharmaceutical composition according to any one of claims 1 to 4, further comprising one or more high-intensity sweeteners.

6. The pharmaceutical composition according to claim 5, wherein the high-intensity sweetener is selected from dipotassium glycyrrhizate, stevia extracts, acesulfame potassium and saccharin sodium.

7. The pharmaceutical composition according to any one of claims 1 to 6, further comprising one or more anti-caking agents.

8. The pharmaceutical composition according to claim 7, wherein the anti-caking agent is selected from light anhydrous silicic acid and cornstarch.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein a dosage form is dry syrup, powder or granules.

The claims defining the invention are as follows:

[1] A pharmaceutical composition comprising:

one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25°C and 70% relative humidity; and

oseltamivir phosphate,

wherein the sugars and sugar alcohols are purified so that an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.

[2] The pharmaceutical composition according to claim 1, wherein the excipient is one sugar or sugar alcohol selected from erythritol, D-mannitol and sucrose or a mixture thereof.

[3] The pharmaceutical composition according to claim 1 or 2, wherein the composition is used for prevention or treatment of influenza virus infection and conditions associated with the infection selected from bronchitis, pneumonia, generalized pain and fever.

[4] The pharmaceutical composition according to any one of claims 1 to 3, further comprising one or more water-soluble polymers selected from povidone, methylcellulose, carmellose sodium and macrogol 6000.

[5] The pharmaceutical composition according to any one of claims 1 to 4, further comprising one or more high-intensity sweeteners.

[6] The pharmaceutical composition according to claim 5, wherein the high-intensity sweetener is selected from dipotassium glycyrrhizate, stevia extracts, acesulfame

potassium and saccharin sodium.

[7] The pharmaceutical composition according to any one of claims 1 to 6, further comprising one or more anti-caking agents.

[8] The pharmaceutical composition according to claim 7, wherein the anti-caking agent is selected from light anhydrous silicic acid and cornstarch.

[9] The pharmaceutical composition according to any one of claims 1 to 8, wherein a dosage form is dry syrup, powder or granules.